Open access
Open access
Powered by Google Translator Translator

Allergy & Immunology

Review: SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19.

17 Oct, 2021 | 21:30h | UTC

SARS-CoV-2 Dose, Infection, and Disease Outcomes for COVID-19 – A Review – Clinical Infectious Diseases

Related: Seroconversion and fever are dose-dependent in a nonhuman primate model of inhalational COVID-19.

 

Commentary from the author on Twitter (thread – click for more)

 


Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines.

17 Oct, 2021 | 21:27h | UTC

News release: Eight months later: Researchers compare immune responses elicited by three COVID-19 vaccines – Beth Israel Deaconess Medical Center

Original study: Differential Kinetics of Immune Responses Elicited by Covid-19 Vaccines – New England Journal of Medicine

 

Commentary on Twitter

 


Study evaluated several heterologous SARS-CoV-2 vaccine regimens; no efficacy data but there was increased antibody production on study days 15 and 29 after booster shots from Moderna and Pfizer.

15 Oct, 2021 | 02:49h | UTC

Heterologous SARS-CoV-2 Booster Vaccinations: Preliminary Report – medRxiv

Commentary: Study: Mixing and Matching COVID-19 Booster Shots Is Effective, Safe – U.S. News

 

Commentary on Twitter

 


A primer on what we know about mixing and matching Covid vaccines.

13 Oct, 2021 | 01:44h | UTC

A primer on what we know about mixing and matching Covid vaccines – STAT

Related:

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 


Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination.

8 Oct, 2021 | 10:29h | UTC

Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England – Eurosurveillance

Related:

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination.

Heterologous Oxford–AstraZeneca and Moderna Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

Heterologous Oxford–AstraZeneca and BioNTech/Pfizer Vaccination induce increased levels of neutralizing antibody compared to 2 doses of Oxford–AstraZeneca.

[Preprint] Mixing Covid jabs has good immune response, study finds – “The Com-Cov trial looked at the efficacy of either two doses of Pfizer, two of AstraZeneca, or one of them followed by the other. All combinations worked well, priming the immune system”.

Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”.

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

Lab study shows a heterologous AstraZeneca + Pfizer immunization strategy provides stronger immunogenicity against Covid compared to homologous AZ + AZ or Pfizer + Pfizer strategies.

RCT: Mixing 2 different Covid vaccines is associated with increased risk of side effects.

 

Commentary on Twitter

 


Review: Eosinophilic Esophagitis.

6 Oct, 2021 | 09:51h | UTC

Eosinophilic Esophagitis: A Review – JAMA (free for a limited period)

Related:

Randomized trial: Budesonide orodispersible tablets maintain remission in patients with eosinophilic esophagitis

Clinical Guidelines for the Management of Eosinophilic Esophagitis

Eosinophilic Esophagitis: Review and Update

 


Editorial | Covid-19 vaccination: evidence of waning immunity is overstated.

3 Oct, 2021 | 22:49h | UTC

Covid-19 vaccination: evidence of waning immunity is overstated – The BMJ

Related:

COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

COVID vaccine effects wane over time but still prevent death and severe illness.

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 


Clinical practice guideline on immune checkpoint inhibitor-related adverse events.

24 Sep, 2021 | 08:55h | UTC

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events – Journal for ImunoTherapy of Cancer

Related:

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (several resources on the subject)

 


Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

23 Sep, 2021 | 10:16h | UTC

Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial – The Lancet Infectious Diseases

Related: Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 


Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.

23 Sep, 2021 | 10:12h | UTC

Clinical Characteristics of Multisystem Inflammatory Syndrome in Adults: A Systematic Review – JAMA Network Open

 

Commentary on Twitter

 


An FDA panel says only high-risk Americans and those 65+ should get covid boosters.

19 Sep, 2021 | 23:45h | UTC

An FDA Panel Says Only High-Risk Americans And Those 65+ Should Get COVID Boosters – NPR

See also:

FDA advisory panel recommends booster doses of Covid-19 vaccine only for older and high-risk Americans – STAT

5 reasons why FDA advisers did not recommend Covid-19 booster shots for everyone – CNN

Top doctors say not so fast to Biden’s boosters-for-all plan – Associated Press

Related:

An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

Third shot: UK to offer COVID booster jabs to over 50s.

COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

COVID vaccine effects wane over time but still prevent death and severe illness.

What’s the evidence for COVID-19 booster shots?

WHO appeals for countries to postpone COVID-19 vaccine boosters until 2022 to prioritize vaccinating the most at-risk people around the world who are yet to receive their first dose.

AstraZeneca bosses warn against rush for boosters – “giving the most vulnerable, who may not have built up a full immune response from the first two, a third, top-up dose is “sensible”. But any decision to give a third, booster jab “to large swathes of the population”, to extend their protection from the first two, must be based on clinical data”.

 


COVID vaccine immunity is waning — how much does that matter? – “As debates about booster shots heat up, what’s known about the duration of vaccine-based immunity is still evolving”.

19 Sep, 2021 | 23:40h | UTC

COVID vaccine immunity is waning — how much does that matter? – Nature

 


Case series: Vaccine-induced thrombocytopenia with severe headache may precede cerebral venous sinus thrombosis by several days – patients with severe headache 5 to 20 days after adenovirus vector vaccination against Covid-19 should undergo immediate testing for thrombocytopenia and d-dimer levels and, if available, testing for anti–PF4–heparin IgG antibodies.

16 Sep, 2021 | 10:14h | UTC

Vaccine-Induced Thrombocytopenia with Severe Headache – New England Journal of Medicine

 

Commentary on Twitter

 


An observational study in Israel suggests additional protection from a 3rd dose of the Pfizer vaccine in individuals 60 years of age or older.

16 Sep, 2021 | 10:13h | UTC

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel – New England Journal of Medicine

 


COVID vaccine effects wane over time but still prevent death and severe illness.

16 Sep, 2021 | 10:10h | UTC

COVID vaccine effects wane over time but still prevent death and severe illness – The Conversation

Related:

Perspective | What we actually know about waning immunity.

Another study shows Pfizer mRNA vaccine immunity is reduced over time.

[Press release – not published yet] Study shows vaccine protection wanes over time, but vaccines still offer good protection against severe disease.

Studies: COVID vaccine protection waning against infection but not hospitalization.

Pfizer says it’s time for a Covid booster; FDA and CDC say not so fast.

 


COVID-19 vaccine efficacy does not support boosters for general population, review concludes.

14 Sep, 2021 | 10:08h | UTC

News release: COVID-19 vaccine efficacy does not support boosters for general population, review concludes – The Lancet

Original article: Considerations in boosting COVID-19 vaccine immune responses – The Lancet

Commentaries:

FDA experts among group opposing US booster shot plan – Associated Press

FDA vaccine regulators argue against Covid-19 vaccine boosters in new international review – STAT

Global experts pan wider use of COVID vaccine booster dose – CIDRAP

Expert reaction to viewpoint article on COVID-19 booster vaccines for general populations – Science Media Centre

Boosters Are ‘Not Appropriate’ – Reach Unvaccinated First – Health Policy Watch

Data Doesn’t Support Need for COVID-19 Vaccine Boosters: Experts – HealthDay

In a new review, some F.D.A. scientists and others say boosters aren’t needed for the general population. – The New York Times

 


What’s the evidence for COVID-19 booster shots?

12 Sep, 2021 | 22:05h | UTC

What’s the evidence for COVID-19 booster shots? – Canadian Medical Association Journal

 


India’s DNA COVID vaccine is a world first – more are coming.

10 Sep, 2021 | 05:30h | UTC

India’s DNA COVID vaccine is a world first – more are coming – Nature

 


COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it.

10 Sep, 2021 | 05:29h | UTC

COVID infections may give more potent immunity than vaccines – but that doesn’t mean you should try to catch it – The Conversation

Original study and commentary: [Preprint] Observational data suggests natural immunity after a SARS-CoV-2 infection confers longer lasting and stronger protection compared to vaccine-induced immunity.

 


Perspective | What we actually know about waning immunity.

10 Sep, 2021 | 05:26h | UTC

What We Actually Know About Waning Immunity – The Atlantic

 


[Preprint] RCT: Additional heterologous vs. homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination.

9 Sep, 2021 | 09:55h | UTC

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomized controlled trial – medRxiv

 

Commentary on Twitter (thread – click for more)

 


Kids and COVID: why young immune systems are still on top.

7 Sep, 2021 | 21:46h | UTC

Kids and COVID: why young immune systems are still on top – Nature

 


[Preprint] M-A of 12.011.447 individuals finds individuals previously infected with SARS-CoV-2 had an 81% reduction in odds of a reinfection.

7 Sep, 2021 | 21:42h | UTC

The prevalence of adaptive immunity to COVID-19 and reinfection after recovery, a comprehensive systematic review and meta-analysis of 12 011 447 individuals – medRxiv

 

Commentary on Twitter

 


Extended intervals and extra doses of the AstraZeneca vaccine are associated with increased immunogenicity.

7 Sep, 2021 | 10:56h | UTC

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002) – The Lancet

Invited commentary: Longer intervals and extra doses of ChAdOx1 nCoV-19 vaccine

 

Commentaries on Twitter

(thread – click for more)

(thread – click for more)

 


Opinion | Video: Immunity is the only way through a pandemic (w/Dr. Monica Gandhi).

7 Sep, 2021 | 10:45h | UTC

Immunity Is The Only Way Through A Pandemic (w/Dr. Monica Gandhi) – ZDoggMD

 


Stay Updated in Your Specialty

No spam, just news.